cis-N-((4-Cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide | 1142090-23-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-N-((4-Cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide
• 英文别名: (1R,3S)-N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide
• CAS: 1142090-23-0
• 化学式: C₂₁H₂₄F₃N₇O
• 分子量: 447.5
• InChiKey: LQHDJQIMETZMPH-ZBFHGGJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• [EN] NOVEL SEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049157A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体来说，该发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m如下所定义，并其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于通过sEH酶介导的疾病治疗，如高血压。因此，该发明进一步涉及包含该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包含该发明的药物组合物来抑制sEH并治疗与之相关的病症的方法。
• NOVEL sEH INHIBITORS AND THEIR USE
  申请人：Ding Yun

  公开号：US20100210656A1

  公开（公告）日：2010-08-19

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m的定义如下，并且其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，例如高血压。因此，本发明还涉及包括本发明化合物的制药组合物。本发明还进一步涉及使用本发明化合物或包括本发明化合物的制药组合物来抑制sEH和治疗与之相关的疾病的方法。
• Novel sEH Inhibitors and Their Use
  申请人：DING Yun

  公开号：US20100249137A1

  公开（公告）日：2010-09-30

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及(Cis)-N-[4-氰基-2-(三氟甲基)苯基]甲基}-3-[4-甲基-6-(甲基氨基)-1,3,5-三嗪-2-基]氨基}环己烷羧酰胺；或其药学上可接受的盐，以及N-[4-氰基-2-(三氟甲基)苯基]甲基}-3-[4-甲基-6-(甲基氨基)-1,3,5-三嗪-2-基]氨基}环己烷羧酰胺；或其药学上可接受的盐。本发明的化合物可用于治疗由sEH酶介导的疾病，如高血压、哮喘和COPD。因此，本发明进一步涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制sEH和治疗与之相关的疾病的方法。
• Methods of treating mental disorders
  申请人：The Regents of the University of California

  公开号：US11123311B2

  公开（公告）日：2021-09-21

  This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

  本发明提供了预防、减轻、改善和/或控制精神疾病的方法，这些精神疾病包括抑郁症、重度抑郁症、双相情感障碍、精神分裂症和药物滥用（包括成瘾和依赖），其方法是施用增加环氧脂肪酸的制剂（如可溶性环氧化物水解酶抑制剂），作为单独的活性制剂或与另一种制剂（如抗抑郁剂、抗精神病药、抗焦虑药）联合施用。当与另一种药物联合用药时，一种或两种药物可以亚治疗剂量给药。
• NOVEL SEH INHIBITORS AND THEIR USE
  申请人：GlaxoSmithKline LLC

  公开号：EP2214487B1

  公开（公告）日：2013-11-27